NEW YORK (GenomeWeb) – SomaLogic said today that it has signed an agreement with Bristol-Myers Squibb to give the drugmaker expanded access to its SOMAmer reagents.
Under the agreement, BMS has access to the 1,310 reagents in the public version of SomaLogic's SOMAscan assay along with a number of custom reagents developed specifically for BMS through SomaLogic's SOMAmer Discovery Service.
Launched in 2012, SOMAscan uses SomaLogic's Slow Off-rate Modified Aptamer, or SOMAmer, affinity reagents to simultaneously quantify more than 1,000 protein analytes. These SOMAmers – essentially short strands of DNA – bind to protein targets in a sample of interest. They can then be quantified via microarrays, with the quantity of a given SOMAmer corresponding to the quantity of its target protein.
The BMS deal is similar to one SomaLogic signed in 2014 giving Novartis access to the standard SOMAscan platform as well as custom reagents.
Financial and other terms of the BMS agreement were not disclosed.